IDYA fills key finance seat with Dr. Joshua Bleharski appointment

Rhea-AI Filing Summary

IDEAYA Biosciences (Nasdaq: IDYA) filed an 8-K disclosing a material C-suite change. On June 26 2025, the Board appointed Joshua Bleharski, Ph.D. as Chief Financial Officer and Principal Financial Officer under Item 5.02. The filing states the appointment is effective immediately and made pursuant to Section 16(a)-1(f) of the Exchange Act.

No resignations, compensation terms, financial guidance or other business updates were provided. Investors should monitor upcoming filings for any strategic or financial initiatives led by the new CFO.

Positive

• Appointment of Chief Financial Officer: Board named Joshua Bleharski, Ph.D. as CFO and Principal Financial Officer, filling a critical C-suite position

Negative

• None.

Insights

Financial Analyst

TL;DR: New CFO named; impact depends on execution, no numbers disclosed.

The company has filled a critical leadership role that oversees budgeting, capital planning and SEC reporting. While leadership stability is generally favorable, the filing lacks detail on Dr. Bleharski’s prior track record, compensation incentives or immediate strategic directives. Without visibility into his mandate or upcoming financing needs, the appointment is neutral for valuation in the short term. Watch for subsequent 8-K or 10-Q disclosures that might outline capital-raising or cost-management initiatives driven by the new CFO.

Corporate Governance Expert

TL;DR: Governance neutral—key post filled, no other board changes.

Filling the Principal Financial Officer slot aligns the company with best-practice governance and Sarbanes-Oxley requirements. Absence of any disclosed departures suggests operational continuity. However, the board did not reveal compensation terms or performance metrics, limiting insight into alignment with shareholder interests. Until further disclosures emerge, the governance impact remains balanced, neither signaling risk nor clear upside.

false 0001676725 0001676725 2025-06-26 2025-06-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2025

IDEAYA Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38915		47-4268251
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

5000 Shoreline Court, Suite 300

South San Francisco, California 94080

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 443-6209

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		IDYA		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

At a meeting held on June 26, 2025, the Board of Directors of IDEAYA Biosciences, Inc. (the “Company”) appointed Joshua Bleharski, Ph.D. as Chief Financial Officer and Principal Financial Officer of the Company under Section 16(a)-1(f) of the Securities Exchange Act of 1934, as amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				IDEAYA BIOSCIENCES, INC.
Date: June 27, 2025				By:		/s/ Yujiro Hata
						Yujiro Hata
						President and Chief Executive Officer

FAQ

Who was appointed CFO of IDEAYA Biosciences (IDYA) on June 26, 2025?

The board appointed Joshua Bleharski, Ph.D. as Chief Financial Officer and Principal Financial Officer.

When is Joshua Bleharski’s appointment as CFO effective?

The filing indicates the appointment was effective June 26 2025, the date of the board meeting.

Did IDEAYA Biosciences report any executive departures in this 8-K?

No. The 8-K only reports the appointment of a new CFO; it does not mention any departures.

Were compensation terms for the new CFO disclosed?

The 8-K did not disclose compensation details or contractual terms for Dr. Bleharski.

What SEC item does this leadership change fall under?

The change is reported under Item 5.02 – Departure or Appointment of Certain Officers.